Is Jupiter Life Lin overvalued or undervalued?

As of 30 April 2025, the valuation grade for Jupiter Life Lin has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 49.60, an EV to EBITDA of 31.97, and a PEG ratio of 2.30, indicating high valuations relative to earnings growth expectations.
In comparison with peers, Jupiter Life Lin's PE ratio is significantly higher than that of Apollo Hospitals Enterprise Ltd. at 69.03 and Narayana Hrudayalaya Ltd. at 44.91, both of which are also classified as expensive. The company's recent stock performance shows a 24.82% return over the past year, outperforming the Sensex's 7.53% return, which may suggest some investor optimism despite the high valuation metrics.